MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Biomet swings to Q4 black, pares fiscal 2013 losses

Biomet swings to Q4 black, pares fiscal 2013 losses

By

Biomet swings to Q4 black, pares fiscal 2013 losses

Biomet said it posted black ink during the 4th quarter and cut its losses for fiscal 2013, reporting a 1.0 % decline in large joint reconstruction sales.

The privately held medical device company, which is said to be considering an IPO or sale, is closely watched as a bellwether for the orthopedic market, which has been bedeviled in recent years by falling procedure volumes for hip and knee replacements.

Biomet reported profits of $20.5 million on sales of $783.9 million for the 3 months ended May 31, representing top-line growth of 6.0%. Warsaw, Ind.-based Biomet reported Q4 losses of $389.1 million last year on a nearly $530 million writedown. Excluding that and other 1-time items, adjusted profits were $133.0 million for Q4 2013, up 26.5% compared with $105.1 million in adjusted profits during the same period last year.

For the full fiscal year, losses were $381.7 million on sales of $3.05 billion, for sales growth of 7.6%. Losses declined 16.8% compared with fiscal 2012, according to a press release.

The news helped push share prices up for Biomet’s peers in the orthopedics sector. Wright Medical (NSDQ:WMGI) stock was trading at $27.76 per share as of about 12:20 p.m. today, up 2.2%; shares of Stryker (NYSE:SYK) gained 1.3%, rising to $67.22 apiece; Smith & Nephew (FTSE:SN, NYSE:SNN) rose 1.7% to $58.63 per share; and Zimmer (NYSE:ZMH) shares gained 1.4%, reaching $78.24 each.

"Our combined hip and knee constant currency growth of 2% for the year was generally in line with the market – not to our standard of clear above-market growth, but we’re working on the product introductions that we believe will return us to that standard," president & CEO Jeffrey Binder said in prepared remarks. "We believe that our large-joint reconstructive business provides us with a strong and stable base and we disagree strongly with those who believe that there are few opportunities for innovation and differentiation. We’re working hard to prove the naysayers wrong."

Earlier this month reports surfaced that Biomet’s private equity owners were putting the company up for sale or considering an IPO.

In case you missed it

RSS From Medical Design & Outsourcing

  • iRhythm stays silent on federal grand jury subpoenas
    More than one year after receiving the first of two federal grand jury subpoenas seeking information about its products and communications with the FDA, iRhythm Technologies has said little publicly about the matter. It would have been easy to miss the San Francisco-based cardiac monitor maker’s initial disclosure last summer. iRhythm (Nasdaq:IRTC) was without a… […]
  • How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
    A lot of talk around Dexcom (Nasdaq:DXCM) in the last couple of years has centered around its next-generation G7 continuous glucose monitor. The latest iteration of the company’s CGM platform has already garnered CE mark this year and awaits FDA approval, with some expectations for that to come after the American Diabetes Association’s Scientific Sessions next month. The company also presented… […]
  • Texas power grid struggles in heat one year after record cold stopped semiconductor plants
    A heat wave in Texas took at least six power plants offline Friday with high temperatures forecasted to blaze throughout this week. A record cold snap in February 2021 took NXP Semiconductors and Samsung chip fabrication facilities offline for weeks, contributing to a global semicondcutor shortage that is still throttling medical device production. There’s no… […]
  • How Stryker includes users for product design in the digital age
    Medical device developers and manufacturers like Stryker (NYSE:SYK) are changing how they approach design as digital technology becomes more crucial. Four Stryker executives shared how the Kalamazoo, Michigan–based orthopedic device giant is thinking differently about medical product development and how health care providers and patients will ultimately use them. The DeviceTalks Boston panel of Stryker… […]
  • DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event
    DermaSensor Inc. — the creator of a handheld, point-and-click device to quickly assess skin lesions for cancer risk — is the winner of the MedTech Innovator Mid-Stage Companies Pitch Event.  The Miami-based mid-stage company beat out 1,000 applicants, more than 20 of which competed on-site May 10–11, 2022 at DeviceTalks Boston. DermaSensor walked away with… […]
  • Steris rises on Street-beating Q4, sets fiscal 2023 guidance
    Steris (NYSE:STE) shares ticked up today on fourth-quarter financial results that came in just ahead of the consensus forecast. The infection prevention technology company — headquartered in Dublin, Ireland, and run operationally out of Mentor, Ohio — posted profits of $52.3 million, or 52¢ per share, on sales of $1.2 billion for the three months… […]
  • Lucira Health asks FDA for EUA on molecular at-home COVID/flu test
    Lucira Health (Nasdaq: LHDX) today said it has asked the FDA for an emergency use authorization (EUA) for its combination COVID-19 and flu test. Emeryville, California–based Lucira said the at-home test would be available with a prescription to test for SARS-CoV-2, Influenza A and Influenza B. The Nucleic Acid Amplification Test (NAAT) platform has a… […]
  • Device commercialization platform AcuityMD raises $31M Series A to fund R&D engineer hiring
    AcuityMD said today it has raised $31 million in Series A funding for its medical device commercialization platform. “With our new funding, we plan to double down on R&D by growing our engineering team from 15 to over 40 over the next year,” AcuityMD co-founder and CEO Michael Monovoukas said in a blog post. “We’ll… […]
  • Rockley Photonics announces $81.5M private placement
    Rockley Photonics (NYSE:RKLY) announced today that it entered into agreements for an $81.5 million private placement. Participating investors agreed to purchase $81.5 million in convertible senior secured notes (due 2026) and warrants to purchase 26.5 million Rockley ordinary shares at an exercise price of $5 per share, subject to certain anti-dilution adjustments. Warrants purchased in… […]
  • Stryker leaders talk medtech trends at DeviceTalks Boston: ‘If you’re slow, you’re going to lose’
    The first day of DeviceTalks Boston closed with a panel of Stryker (NYSE:SYK) executives discussing new tools, technologies and strategies in medtech. Digital VP Tracy Robertson, Digital, Robotics, and Enabling Technologies President Robert Cohen and Surgical Technologies VP of Digital Innovation Siddarth Satish offered their thoughts on industry trends in healthcare and at the Kalamazoo,… […]
  • Medtronic’s VC leader discusses risk, returns, strategy and an ‘ugly truth’
    A panel of medtech investors convened today for DeviceTalks Boston included David Neustaedter, VP of venture capital at Medtronic (NYSE: MDT). He’s spent 14 years in the role, including as director of venture capital at Covidien before Medtronic acquired the company. (Read more in his DeviceTalks speaker bio.) Medtronic has more than $500 million in… […]

Leave a Reply